|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2020
12 months to Jun 30, 2021
|
|
|---|---|---|---|---|---|
| Cash flow from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Fair value of common stock issued related to loan amendment | |||||
| Cumulative translation adjustments recognized in earnings as part of the reorganization of foreign subsidiaries | |||||
| Loss on issuance under credit agreement | |||||
| Change in fair value of long-term debt | |||||
| Change in fair value of warrant liability | |||||
| Depreciation and amortization | |||||
| Stock-based compensation | |||||
| Non-cash lease expense | |||||
| Loss on fixed asset disposal | |||||
| Investment losses | |||||
| Patent impairment loss | |||||
| Loss on patent disposal | |||||
| Remeasurement and foreign currency transaction loss | |||||
| Excess and obsolete inventory related charges | |||||
| BARDA deferred costs | |||||
| Contract cost amortization | |||||
| Provision for credit losses | |||||
| Amortization of premium of marketable securities | |||||
| Non-cash changes in the fair value of NQDC plan | |||||
| Changes in operating assets and liabilities: | |||||
| Trade and other receivables | |||||
| BARDA receivables | |||||
| Prepaids and other current assets | |||||
| Inventory | |||||
| Operating lease liability | |||||
| Corporate-owned life insurance ("COLI") asset | |||||
| Other long-term assets | |||||
| Accounts payable and accrued expenses | |||||
| Accrued wages and fringe benefits | |||||
| Current non-qualified deferred compensation liability | |||||
| Other current liabilities | |||||
| Non-qualified deferred compensation plan liability | |||||
| Contract liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flow from investing activities: | |||||
| Purchase of marketable securities | |||||
| Sale of marketable securities | |||||
| Maturities of marketable securities | |||||
| Purchase of plant and equipment | |||||
| Capitalized software development costs | |||||
| Patent filing fees | |||||
| Net cash provided by investing activities | |||||
| Cash flow from financing activities: | |||||
| Proceeds from long-term debt | |||||
| Proceeds from private placement of common stock | |||||
| Issuance costs associated with private placement | |||||
| Proceeds from exercise of stock options | |||||
| Employee stock purchase plan ("ESPP") purchases | |||||
| Net cash provided by financing activities | |||||
| Effect of foreign exchange rate on cash and cash equivalents | |||||
| Net decrease in cash and cash equivalents | |||||
| Cash and cash equivalents beginning of the period | |||||
| Cash and cash equivalents end of the period | |||||
| Supplemental Disclosure of Cash Flow Information: | |||||
| Income taxes paid during the period | |||||
| Interest paid during the period | |||||
| Non-cash investing activities: | |||||
| Intangible asset purchase not yet paid | |||||
| Capital expenditures not yet paid | |||||
| Right-of-use-asset obtained in exchange for lease liabilities | |||||
| Warrant liability recognized upon issuance of term loan | |||||
Loading...